Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of YPEG-Filgrastim in Chemotherapy Patients

NCT01238562 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
30
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Xiamen Amoytop Biotech Co., Ltd.

Collaborators